Inovio Stock Story

INO
 Stock
  

USD 2.11  0.25  10.59%   

Inovio Pharma Tangible Asset Value is quite stable at the moment as compared to the past year. The company's current Tangible Asset Value is estimated at 520.92 Million. Working Capital is expected to rise to about 412.9 M this year, although the value of Net Income Per Employee will most likely fall to (785.9 K). In this article, we will outline Inovio Pharma as a potential position in addition to your existing holdings. We will inspect why it could be a game-changer for Inovio Pharma institutional investors.
Published over three months ago
View all stories for Inovio Pharma | View All Stories

Should you continue to rely on Inovio Pharma (NASDAQ:INO) management?

About 38.0% of the company shares are owned by institutional investors. Insiders ownership of Inovio Pharma refers to the amount of Inovio Pharma equity owned by Inovio officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Inovio, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Inovio Pharma. Regardless of method or technology, to accurately forecast the stock or bond market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Inovio Pharma

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Inovio Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Inovio Pharma in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inovio Pharma. Your research has to be compared to or analyzed against Inovio Pharma's peers to derive any actionable benefits. When done correctly, Inovio Pharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Inovio Pharma.

How important is Inovio Pharma's Liquidity

Inovio Pharma financial leverage refers to using borrowed capital as a funding source to finance Inovio Pharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Inovio Pharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Inovio Pharma's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Inovio Pharma, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Simon Benito of 2000 shares of Inovio Pharma subject to Rule 16b-3

Legal trades by Inovio Pharma insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Inovio insider trading alert for exercise of common stock options by Simon Benito, the corporate stakeholder, on 20th of July 2022. This event was filed by Inovio Pharmaceuticals In with SEC on 2022-07-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Inovio Pharma exhibits very low volatility with skewness of 0.15 and kurtosis of -0.87. However, we advise investors to further study Inovio Pharma technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Inovio Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Inovio Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Inovio Pharma Implied Volatility

Inovio Pharma's implied volatility exposes the market's sentiment of Inovio Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inovio Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inovio Pharma stock will not fluctuate a lot when Inovio Pharma's options are near their expiration.

Returns Breakdown

Return on Investment(54.96)
Return on Assets(0.58)
Return on Equity(0.68)
Return Capital(0.7)
Return on Sales(174.48)

Time to exit Inovio Pharma is now

Inovio Pharma total risk alpha is up to -0.01. Inovio Pharma exhibits very low volatility with skewness of 0.15 and kurtosis of -0.87. However, we advise investors to further study Inovio Pharma technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Inovio Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Inovio Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Inovio Pharma Implied Volatility

Inovio Pharma's implied volatility exposes the market's sentiment of Inovio Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inovio Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inovio Pharma stock will not fluctuate a lot when Inovio Pharma's options are near their expiration.

Our Takeaway on Inovio Pharma Investment

Whereas other companies in the biotechnology industry are either recovering or due for a correction, Inovio Pharma may not be performing as strong as the other in terms of long-term growth potentials. To conclude, as of the 7th of May 2022, our research shows that Inovio Pharma is a rather relatively risky investment opportunity with a low chance of distress in the next two years. From a slightly different view, the entity currently appears to be undervalued. Our latest 90 days buy-or-sell advice on the company is Cautious Hold.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Inovio Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com